JCO Early Release, published online ahead of print Aug 8 2005
Journal of Clinical Oncology, 10.1200/JCO.2005.06.075
Received June 9, 2004
Accepted May 4, 2005
Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer
William P. Petros *, Penelope J. Hopkins , Susan Spruill , Gloria Broadwater , James J. Vredenburgh , O. Michael Colvin , William P. Peters , Roy B. Jones , Jeff Hall , and Jeffrey R. Marks
From the West Virginia University Health Sciences Center, Morgantown, WV; Duke University Medical Center, Durham, NC; and DNA Sciences Inc, Fremont, CA.
* To whom correspondence should be addressed. E-mail: wpetros{at}hsc.wvu.edu
Purpose: To evaluate associations between patient survival, pharmacokinetics, and drug metabolism-related genetic polymorphisms in patients receiving a combination chemotherapy regimen for breast cancer.
Patients and Methods: A genotype association study was conducted on 85 chemotherapy-naïve patients with metastatic or inflammatory breast cancer that were evaluated for an extended period after receiving standard-dose chemotherapy followed by high-dose cyclophosphamide, cisplatin, and carmustine. Blood pharmacokinetics were evaluated, and DNA was genotyped for 29 polymorphisms in 17 drug metabolism genes.
Results: Patients with cyclophosphamide plasma exposures above the median (implying slower metabolic activation) had a shorter survival than those below the median (1.8 v 3.8 years, respectively; P = .042). Patients having a variant genotype of cytochrome P450 3A4 displayed higher blood concentrations of parent (inactive) cyclophosphamide with the second and third doses (P = .024 and .028, respectively) in addition to slower cyclophosphamide activation over the three doses (P = .031). Median survival for these patients was 1.3 years compared with 2.7 years for those without the variant (P = .043). Similar results were observed for patients carrying a genetic variant of P450 3A5. Median survival for patients with deletions of glutathione-S-transferase M1 gene was 3.5 v 1.5 years for patients with one or both copies (P = .041). Patients with a polymorphism in a gene regulating metallothionein had lower platinum concentrations and shorter survival (P = .033).
Conclusion: These data suggest that pretreatment evaluation of drug metabolism genes may explain some interindividual differences in both anticancer drug pharmacokinetics and response. The correlations found here may have implications for other commonly used anticancer drugs.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
B. B. Y. Ma, E. P. Hui, S. C. C. Wong, S. Y. Tung, K. K. Yuen, A. King, S. L. Chan, S. F. Leung, M. K. Kam, B. K. H. Yu, et al.
Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms
Ann. Onc.,
November 1, 2009;
20(11):
1854 - 1859.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. O'Donnell and M. E. Dolan
Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
Clin. Cancer Res.,
August 1, 2009;
15(15):
4806 - 4814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Emmenegger, Y. Shaked, S. Man, G. Bocci, I. Spasojevic, G. Francia, A. Kouri, R. Coke, W. Cruz-Munoz, S. M. Ludeman, et al.
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice
Mol. Cancer Ther.,
August 1, 2007;
6(8):
2280 - 2289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Wang, H. Huang, H. Li, D. G. Teotico, M. Sinz, S. D. Baker, J. Staudinger, G. Kalpana, M. R. Redinbo, and S. Mani
Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs
Clin. Cancer Res.,
April 15, 2007;
13(8):
2488 - 2495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al.
Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy
J. Clin. Oncol.,
April 20, 2006;
24(12):
1883 - 1891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
